citral has been researched along with Ischemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmadi, N; Divar, MR; Ganjiani, V; Meimandi-Parizi, A; Mirghazanfari, SM; Rezakhaniha, B; Shrifiyazdi, H; Siroosbakht, S | 1 |
| Ganev, EG; Hiruma-Lima, CA; Martins, DF; Mazzardo-Martins, L; Nishijima, CM; Rocha, LR; Santos, AR | 1 |
2 other study(ies) available for citral and Ischemia
| Article | Year |
|---|---|
The evaluation of citral effects on experimental unilateral testicular ischemia/reperfusion injury.
Topics: Animals; Humans; Ischemia; Male; Malondialdehyde; Oxidative Stress; Rats; Reperfusion Injury; Semen; Spermatic Cord Torsion; Testis; Testosterone | 2022 |
Citral: a monoterpene with prophylactic and therapeutic anti-nociceptive effects in experimental models of acute and chronic pain.
Topics: Acute Pain; Acyclic Monoterpenes; Analgesics; Animals; Capsaicin; Chronic Pain; Excitatory Amino Acids; Formaldehyde; Glutamic Acid; Hyperalgesia; Ischemia; Ketanserin; Male; Mice; Monoterpenes; Neuralgia; Pain, Postoperative; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Stomach Ulcer; Substance P; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2014 |